How is Pfizer responding to COVID-19 - Dreambird clinical trial

March 25th, 2020

To avoid adding to the demands on the healthcare system during this unprecedented crisis with COVID-19, Pfizer is pausing for three weeks the recruitment portion of the company's new and ongoing global interventional clinical studies.
Pfizer is taking this action in the interests of public health so that the company clinical site partners and Pfizer can concentrate on caring for patients in our ongoing clinical trials.

The pause will not affect China, Japan, and South Korea, where recruitment will continue. This pause will also not apply to trials that are recruiting individuals with life-threatening conditions who have few or no other therapeutic options, including several oncology studies and our DMD gene therapy program. In addition, this decision will not affect studies that are already fully recruited.

Patients in our ongoing trials will not be impacted by this decision.
Pfizer has an important responsibility to the patients currently in clinical trials. This decision will allow Pfizer investigators and the company to focus on those individuals.

The company will review this decision in three weeks and provide another update then. Pfizer expects over time to resume recruitment and a new study starts on a country-by-country basis.

 
Sources: Pfizer - How Pfizer is responding